Ensuring quality in studies linking cancer registries and biobanks

Abstract The Nordic countries have a long tradition of providing comparable and high quality cancer data through the national population-based cancer registries and the capability to link the diverse large-scale biobanks currently in operation. The joining of these two infrastructural resources can provide a study base for large-scale studies of etiology, treatment and early detection of cancer. Research projects based on combined data from cancer registries and biobanks provides great opportunities, but also presents major challenges. Biorepositories have become an important resource in molecular epidemiology, and the increased interest in performing etiological, clinical and gene-environment-interaction studies, involving information from biological samples linked to population-based cancer registries, warrants a joint evaluation of the quality aspects of the two resources, as well as an assessment of whether the resources can be successfully combined into a high quality study. While the quality of biospecimen handling and analysis is commonly considered in different studies, the logistics of data handling including the linkage of the biobank with the cancer registry is an overlooked aspect of a biobank-based study. It is thus the aim of this paper to describe recommendations on data handling, in particular the linkage of biobank material to cancer registry data and the quality aspects thereof, based on the experience of Nordic collaborative projects combining data from cancer registries and biobanks. We propose a standard documentation with respect to the following topics: the quality control aspects of cancer registration, the identification of cases and controls, the identification and use of data confounders, the stability of serum components, historical storage conditions, aliquoting history, the number of freeze/thaw cycles and available volumes.

[1]  T. Grimsrud,et al.  Stability of selected serum proteins after long-term storage in the Janus Serum Bank , 2009, Clinical chemistry and laboratory medicine.

[2]  Bjørn Møller,et al.  Data quality at the Cancer Registry of Norway: an overview of comparability, completeness, validity and timeliness. , 2009, European journal of cancer.

[3]  F. Bray,et al.  Evaluation of data quality in the cancer registry: principles and methods Part II. Completeness. , 2009, European journal of cancer.

[4]  F. Bray,et al.  Evaluation of data quality in the cancer registry: principles and methods. Part I: comparability, validity and timeliness. , 2009, European journal of cancer.

[5]  S. Tretli,et al.  Association between serum 25(OH)D and death from prostate cancer , 2009, British Journal of Cancer.

[6]  F. Bray,et al.  Completeness of invasive cervical cancer at the Cancer Registry of Norway , 2009, Acta oncologica.

[7]  L. Holmberg,et al.  The completeness of the Swedish Cancer Register – a sample survey for year 1998 , 2009, Acta oncologica.

[8]  E. Arjas,et al.  Nested case–control data utilized for multiple outcomes: a likelihood approach and alternatives , 2008, Statistics in medicine.

[9]  M. Hansson,et al.  Ethics and biobanks , 2008, British Journal of Cancer.

[10]  C. Wild,et al.  Environmental exposure measurement in cancer epidemiology. , 2008, Mutagenesis.

[11]  Paul Elliott,et al.  The UK Biobank sample handling and storage validation studies. , 2008, International journal of epidemiology.

[12]  P. Elliott,et al.  The UK Biobank sample handling and storage protocol for the collection, processing and archiving of human blood and urine. , 2008, International journal of epidemiology.

[13]  Paolo Toniolo,et al.  Effect of long-term storage on hormone measurements in samples from pregnant women: The experience of the Finnish Maternity Cohort , 2008, Acta oncologica.

[14]  Lars Mørkrid,et al.  Long‐term stability of serum components in the Janus Serum Bank , 2008, Scandinavian journal of clinical and laboratory investigation.

[15]  Joakim Dillner,et al.  Ethical framework for previously collected biobank samples , 2007, Nature Biotechnology.

[16]  J. Carlson,et al.  Assessing quality and functionality of DNA from fresh and archival dried blood spots and recommendations for quality control guidelines. , 2007, Clinical chemistry.

[17]  Pär Stattin,et al.  Nordic biological specimen banks as basis for studies of cancer causes and control – more than 2 million sample donors, 25 million person years and 100 000 prospective cancers , 2007, Acta oncologica.

[18]  Bo Franzén,et al.  Frozen tissue biobanks. Tissue handling, cryopreservation, extraction, and use for proteomic analysis , 2006, Acta oncologica.

[19]  Paolo Vineis,et al.  Design Options for Molecular Epidemiology Research within Cohort Studies , 2005, Cancer Epidemiology Biomarkers & Prevention.

[20]  Kestutis Sasnauskas,et al.  Maternal human polyomavirus infection and risk of neuroblastoma in the child , 2005, International journal of cancer.

[21]  M. Kenward,et al.  Blood biochemistry and the risk of cancer Effect of sample pooling , 2004 .

[22]  Brenda Eskenazi,et al.  Biological sample collection and processing for molecular epidemiological studies. , 2003, Mutation research.

[23]  N E Day,et al.  European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection , 2002, Public Health Nutrition.

[24]  M Plebani,et al.  Mistakes in a stat laboratory: types and frequency. , 1997, Clinical chemistry.

[25]  A. Andersen,et al.  Experiences of the Janus Serum Bank in Norway. , 1995, Environmental health perspectives.

[26]  H. Storm,et al.  Completeness of cancer registration in Denmark 1943-1966 and efficacy of record linkage procedures. , 1988, International journal of epidemiology.

[27]  J H Lubin,et al.  Biased selection of controls for case-control analyses of cohort studies. , 1984, Biometrics.

[28]  J. Karvanen,et al.  Epidemiologic Perspectives & Innovations Open Access Case-cohort Design in Practice – Experiences from the Morgam Project , 2007 .

[29]  M. Kenward,et al.  Blood biochemistry and the risk of cancer. , 2004, Acta oncologica.

[30]  Pär Stattin,et al.  Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: A longitudinal, nested case‐control study in the Nordic countries , 2004, International journal of cancer.

[31]  M. Lehtonen,et al.  Data quality and quality control of a population-based cancer registry. Experience in Finland. , 1994, Acta oncologica.